Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 203 Product development pipeline Key BLA Biological License Application In-license or other alliance relationship with third party MAA Marketing Authorisation Application Europe S Month of first submission NDA New Drug Application USA A Month of first regulatory approval for MAA, this is the first EU approval letter Phase I Evaluation of clinical pharmacology, usually conducted in volunteers Phase II Determination of dose and initial evaluation of efcacy, conducted in a AL CR Month Approvable or Complete Response Letter received indicates that ultimately approval may be given subject to resolution of small number of patients outstanding queries Phase III Large comparative study compound versus placebo and or established PO Month of EU Positive Opinion treatment in patients to establish clinical benefit and safety TA FDA Tentative Approval MAA and NDA BLA Regulatory milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Biopharmaceuticals 933776 beta amyloid monoclonal antibody Alzheimers disorders I 1070806 IL18 monoclonal antibody metabolic disease I 1223249 NOGO-A monoclonal antibody amyotrophic lateral sclerosis & multiple sclerosis I 2401502 domain antibody targetted multi-component malignant melanoma I vaccine 2586881 APN01 recombinant human angiotensin converting acute respiratory distress syndrome I anzyme 2 iboctadekin Doxil IL18 immunomodulator topoisomerase II ovarian cancer I inhibitor otelixizumab anti-CD3 monoclonal antibody i. v. Graves eye disease I otelixizumab anti-CD3 monoclonal antibody s. c. & i. v. rheumatoid arthritis I otelixizumab anti-CD3 monoclonal antibody s. c. type 1 diabetes I 249320 myelin-associated glycoprotein monoclonal stroke II antibody 315234 oncostatin M monoclonal antibody rheumatoid arthritis II 768974 parathyroid hormone osteoporosis II albiglutide glucagon-like peptide 1 GLP 1 agonist heart failure II Benlysta anti-B lymphocyte stimulator monoclonal systemic lupus erythematosus II antibody s. c. mepolizumab anti-IL5 monoclonal antibody severe asthma & nasal polyposis II ofatumumab anti-CD20 human monoclonal antibody s. c. multiple sclerosis II ofatumumab anti-CD20 human monoclonal antibody s. c. rheumatoid arthritis II otelixizumab anti-CD3 monoclonal antibody i. v. myaesthenia gravis II albiglutide GLP 1 agonist type 2 diabetes III Arzerra anti-CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy & use III in relapsed patients Arzerra anti-CD20 human monoclonal antibody diffuse large B cell lymphoma relapsed patients III Arzerra anti-CD20 human monoclonal antibody follicular lymphoma refractory & relapsed patients III otelixizumab anti-CD3 monoclonal antibody i. v. type 1 diabetes III Benlysta anti-B lymphocyte stimulator monoclonal systemic lupus erythematosus Submitted S: Jun10 S: Jun10 antibody i. v. denosumab anti-receptor activator for nuclear kappa bone metastatic disease Submitted N A N A RANK ligand human monoclonal antibody Arzerra anti-CD20 human monoclonal antibody chronic lymphocytic leukaemia refractory patients Approved A: Apr10 A: Oct09 Prolia anti-RANK ligand human monoclonal antibody hormone ablative chemotherapy bone loss in prostate Approved N A N A cancer patients Prolia anti-RANK ligand human monoclonal antibody postmenopausal osteoporosis Approved A: May10 N A Cardiovascular & Metabolic 1614235 sodium dependent glucose transport SGLT1 type 2 diabetes I inhibitor 2245840 SIRT1 activator sarcopaenia also COPD & psoriasis I 256073 high afnity nicotinic acid receptor HM74A metabolic disorders II agonist 557296 oxytocin antagonist premature ejaculation II 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II 1278863 prolyl hydroxylase inhibitor peripheral arterial disease II 1292263 G-protein coupled receptor 119 GRP119 metabolic disorders II agonist 1521498 mu-opioid receptor inverse agonist compulsive eating disorders II 2245840 SIRT1 activator type 2 diabetes also COPD & psoriasis II losmapimod p38 kinase inhibitor cardiovascular disease also COPD & pain II retosiban oxytocin antagonist threatened pre-term labour II rilapladib Lp-PLA2 inhibitor atherosclerosis II darapladib Lp-PLA2 inhibitor atherosclerosis III Arixtra synthetic factor Xa inhibitor treatment of acute coronary syndrome Approved A: Aug07 AL: Feb07 & Sep07 GSK Annual Report 2010 204 Product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Infectious Diseases 2251052 leucyl t-RNA synthetase inhibitor oral & i. v. bacterial infections I 2336805 hepatitis C virus inhibitor hepatitis C I 2485852 hepatitis C virus inhibitor hepatitis C I 1322322 polypeptide deformylase inhibitor bacterial infections II tafenoquine 8-aminoquinoline Plasmodium vivax malaria II Relenza neuraminidase inhibitor i. v. inuenza III Neurosciences 2018682  receptor 1 S1P1 multiple sclerosis I agonist 239512 histamine H3 antagonist dementia & schizophrenia II 649868 orexin antagonist sleep disorders II 742457 5HT6 antagonist dementia II rategrast dual alpha4 integrin antagonist VLA4 multiple sclerosis II Horizant voltage-gated calcium channel modulator post-herpetic neuralgia II N A losmapimod p38 kinase inhibitor pain also cardiovascular disease & COPD II orvepitant NK1 antagonist depression & anxiety II IPX066 dopamine precursor DOPA decarboxylase Parkinsons disease III N A inhibitor Horizant voltage-gated calcium channel modulator restless legs syndrome Submitted S: Sep08, Jan09 & Oct10 Trobalt Potiga neuronal potassium channel opener epilepsy - partial seizures Submitted PO: Jan11 CR: Nov10 retigabine ezogabine Oncology 2110183 AKT protein kinase inhibitor cancer I 2126458 Pi3 kinase inhibitor cancer I 2141795 AKT protein kinase inhibitor cancer I 2256098 focal adhesion kinase inhibitor cancer I vestipitant NK1 antagonist i. v. post operative nausea & vomiting I 1120212 BKM120 mitogen-activated protein kinase inhibitor cancer I MEK1 2 Pi3 alpha kinase inhibitor 1120212 MEK1 2 inhibitor pancreatic cancer II 1120212 2118436 MEK1 2 inhibitor BRaf protein kinase inhibitor metastatic melanoma II 2285921 thrombopoietin receptor agonist thrombocytopaenia II foretinib  transition factor papillary renal cell carcinoma and other cancers II C-met kinase inhibitor Revolade Promacta thrombopoietin receptor agonist oncology-related thrombocytopaenia II 1120212 MEK1 2 inhibitor metastatic melanoma III 2118436 BRaf protein kinase inhibitor metastatic melanoma III Votrient multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy III Revolade Promacta thrombopoietin receptor agonist chronic liver disease induced thrombocytopaenia III Revolade Promacta thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor breast cancer, adjuvant therapy III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor gastric cancer III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma resectable disease III Votrient multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy III Votrient multi-kinase angiogenesis inhibitor sarcoma III Votrient Tyverb Tykerb multi-kinase angiogenesis inhibitor inammatory breast cancer III Her2 and EGFR dual kinase inhibitor Avodart 5-alpha reductase inhibitor reduction in the risk of prostate cancer Submitted S: Sep09 & CR: Jan11 Mar10 Duodart Jalyn 5-alpha reductase inhibitor alpha blocker benign prostatic hyperplasia - xed dose combination Approved A: Mar10 A: Jun10 Revolade Promacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura Approved A: Mar10 A: Nov08 Tyverb Tykerb Her2 and EGFR dual kinase inhibitor breast cancer, first line therapy Approved A: Jun10 A: Jan10 Votrient multi-kinase angiogenesis inhibitor renal cell cancer Approved A: Jun10 A:Oct09 Ophthalmology pazopanib multi-kinase angiogenesis inhibitor oral age-related macular degeneration also cancer indications I pazopanib multi-kinase angiogenesis inhibitor eye drops age-related macular degeneration II GSK Annual Report 2010 Shareholder information P192P212 Business review P08P57 Governance and remuneration P58P101 Financial statements P102P191 Shareholder information P192P212 205 Product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory & Immuno-inammation 610677 p38 kinase inhibitor inhaled COPD I 705498 transient receptor potential vanilloid TRPV1 pruritis I antagonist topical 1322888 motilin receptor agonist delayed gastric emptying I 1325756 chemokine receptor CXCR2 antagonist COPD I 1440115 urotensin antagonist asthma I 2245840 SIRT1 activator COPD also type 2 diabetes & sarcopaenia I 2245840 SIRT1 activator psoriasis also type 2 diabetes & sarcopaenia II 256066 PDE4 inhibitor inhaled COPD II 656933 chemokine receptor CXCR2 antagonist cystic brosis II 685698 glucocorticoid agonist asthma II 681323 p38 kinase inhibitor i. v. acute lung injury & acute respiratory distress syndrome II 705498 transient receptor potential vanilloid TRPV1 non-allergic rhinitis II antagonist intranasal 870086 novel glucocorticoid agonist inhaled asthma II 870086 novel glucocorticoid agonist topical atopic dermatitis II 961081 muscarinic antagonist, beta2 agonist COPD II 962040 motilin receptor agonist delayed gastric emptying II 1399686 anti-inammatory macrolide conjugate oral inammatory bowel disease II 2190915  protein FLAP asthma II inhibitor losmapimod p38 kinase inhibitor oral COPD also cardiovascular disease & pain II 573719 muscarinic acetylcholine antagonist COPD III 573719 vilanterol muscarinic acetylcholine antagonist COPD III 642444 long-acting beta2 agonist vilanterol 642444 long-acting beta2 agonist COPD III 1605786 CCX282 CCR9 antagonist Crohns disease III Relovair vilanterol 685698 long-acting beta2 agonist asthma III glucocorticoid agonist Relovair vilanterol 685698 long-acting beta2 agonist COPD III glucocorticoid agonist Paediatric Vaccines Heptavalent combination conjugated Neisseria meningitis C, Haemophilus inuenzae type b, II vaccine diphtheria, Hepatitis B, tetanus, pertussis and poliomyelitis disease prophylaxis MMR live attenuated measles, mumps, rubella prophylaxis II USA A: Oct03 S. pneumoniae paediatric recombinant conjugated Streptococcus pneumoniae disease prophylaxis II next generation Mosquirix recombinant malaria prophylaxis Plasmodium falciparum III N A Nimenrix MenACWY-TT conjugated Neisseria meningitis groups A, C, W & Y disease prophylaxis Submitted MenHibrix conjugated Neisseria meningitis groups C & Y & Haemophilus inuenzae Submitted N A CR: Jun10 Hib-MenCY-TT type b disease prophylaxis Other Vaccines Flu pandemic cell-culture based H5N1 vaccine pandemic inuenza prophylaxis I HIV recombinant HIV disease prophylaxis I HIV recombinant HIV disease immunotherapy II Tuberculosis recombinant tuberculosis prophylaxis II Flu vaccine inactivated split quadrivalent seasonal inuenza prophylaxis III Zoster recombinant Herpes Zoster prevention III Flu prepandemic H5N1 inactivated split monovalent Quebec pre-pandemic & pandemic inuenza prophylaxis Submitted N A S:Jun09 Canada Pumarix H5N1 inactivated split monovalent Quebec pandemic inuenza prophylaxis Submitted PO: Nov10 N A GSK Annual Report 2010 206 Product development pipeline Achieved Regulatory review milestones Compound Type Indication Phase MAA NDA BLA Antigen Specic Cancer Immunotherapeutic ASCI PRAME recombinant treatment of metastatic melanoma I PRAME recombinant treatment of resectable non-small cell lung cancer I NY-ESO-1 recombinant treatment of metastatic melanoma I WT1 recombinant treatment of acute myelogenous leukaemia II MAGE-A3 recombinant treatment of melanoma III MAGE-A3 recombinant treatment of non-small cell lung cancer III Rare Diseases 2402968 antisense oligonucleotide Duchenne muscular dystrophy III 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune deficiency III ADA-SCID migalastat HCl pharmacological chaperone Fabry disease III Stiefel late stage assets only tazarotene foam retinoid foam acne vulgaris III Duac low dose clindamycin benzoyl peroxide gel acne vulgaris Submitted S: Nov10 Sorilux vitamin D3 analog mild to moderate plaque psoriasis Approved A: Oct10 calcipotriene foam itraconazole tablets oral anti-fungal onychomycosis Approved A: Apr10 Veltin antibiotic retinoid gel acne vulgaris Approved A: Jul10 HIV ViiV Healthcare 1265744 HIV integrase inhibitor long-acting formulation HIV infections I 2248761 non-nucleoside reverse transcriptase inhibitor HIV infections II PF-232798 CCR5 antagonist HIV infections II UK-453061 non-nucleoside reverse transcriptase inhibitor HIV infections II 1349572 HIV integrase inhibitor HIV infections III 1349572 abacavir HIV integrase inhibitor reverse transcriptase HIV infections III sulphate lamivudine inhibitors xed dose combination Option-based alliances with third parties that include assets in Phase I or later development: Company Disease Area Phase Cancer Research UK cancer I ChemoCentryx inammatory disease I & II Galapagos autoimmune disease I OncoMed Pharmaceuticals oncology I Prosensa Therapeutics neuroscience I Ranbaxy Laboratories respiratory I Theravance pain I Telethon Institute for Gene Therapy stem cell gene therapy I & II Afris Alzheimers disease treatment vaccine II Nabi nicotine vaccine III Two assets GSK Annual Report 2010 Shareholder information P192P212
